53 results on '"Jimeno J"'
Search Results
2. Accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with high-dose-rate brachytherapy (HDR)
3. Capsaicin patch 179 mg (CP) for the management of localized neuropathic pain (LNP) after breast cancer (BC) treatment
4. Impact of musical training in breast cancer patients with post-treatment cognitive, funtional and emotional sequelae
5. Characterization of differential metabolic phenotypes and PT-112-induced mitochondrial effects in human prostate cancer cells
6. Long-term outcomes of patients following hospitalization for coronavirus disease 2019: a prospective observational study
7. PT-112, a first-in-class pyrophosphate-platinum conjugate, selectively targets highly glycolytic tumor cells
8. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso parte II: estadificación, tratamiento, pronóstico y seguimiento
9. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso (I): epidemiología, patogenia, clínica y diagnóstico
10. Unmet needs of recently diagnosed breast cancer patients differ depending on specific personal factors: Data from a Spanish cohort
11. A microbiome based model of anticancer intervention
12. Findings across pre-clinical models in the development of PT-112, a novel investigational platinum-pyrophosphate anti-cancer agent
13. Return to work after general surgery: A comparative study
14. 478 Pharmacological disruption of the Astrocytic Elevated Gene-1 (AEG1) in anticancer intervention: PB0412_3 (PB03) as a first-in-class AEG1 interacting agent
15. Lista de espera en Cirugía General y Digestiva: expectativas del paciente, calidad de vida durante la espera y grado de satisfacción
16. Forecasting flexibility in electricity demand with price/consumption volume signals
17. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
18. 292 Role of the epithelial phenotype in the sensitivity of pancreatic and breast cancer cell lines to Irvalec; in vitro synergism of the combination with gemcitabine
19. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
20. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
21. 317 POSTER Antiproliferative effects of PM02734, a novel marine cyclic peptide compared with currently used Erb-B inhibitors, in a panel of human cancer cell lines characterised for Erb-B expression
22. 7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas
23. Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
24. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
25. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia
26. A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours
27. Progress in the development and acquisition of anticancer agents from marine sources
28. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells
29. 638 Pharmacodynamics of apilidinR (APL) in experimental models of haematological malignancies (HAMA)
30. Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
31. 573 Safety profile for yondelis (ET-743) 1.3 mg/m2 over 3 hours (h)
32. The combination of yondelis and cisplatin is synergistic against human tumor xenografts
33. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors
34. Differentiation of Facultatively Heterofermentative Lactobacilli from Plants, Milk, and Hard Type Cheeses by SDS-PAGE, RAPD, FTIR, Energy Source Utilization and Autolysis Type
35. Book Review
36. In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells
37. Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound
38. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer
39. Phase I trials with ET-743, a marine derived (MD) anticancer agent
40. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
41. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
42. Biological activity of thiocoraline, a novel marine depsipeptide
43. Phase I clinical study of ecteinascidin-743 (ET-743) as a 24 hours continuous intravenous infusion (CI) in patients (pts) with solid tumors (st): A progress report
44. Phase I and pharmacokinetic study of ecteinascldin-743 (ET-743) given as a one hour infusion every 21 days
45. Schedule-clependent myelotoxlclty induced in vitro by the new marine derived minor groove interacting agent ecteinascldln 743
46. Ripening of Emmental Cheese Wrapped in Foil with and without Addition ofLactobacillus caseisubsp.casei. I. Microbial, Chemical, Rheological and Sensorial Investigations
47. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study
48. 24 O - Ecteinascidin-743 (ET743) : in vitro (IVT) and in vivo (INY) results in solid tumor models
49. 109 Ecteinascidin (ET) 743: Developmental status of a marine (M) derived anticancer compound (AC)
50. 122 Marine (MA) depsipeptides (DEP) with activity (A) against solid tumours (ST) models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.